Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT05120830
Active, not recruiting Phase 1/2

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Intellia Therapeutics
Phase
Phase 1/2
Started
2021-12-10
Last updated
2026-09-25

Condition(s) studied

Hereditary Angioedema

Investigational drug(s) / intervention(s)

Biological NTLA-2002Normal Saline IV Administration

Biological NTLA-2002: CRISPR/Cas9 gene editing system delivered by LNP for IV administration

Normal Saline IV Administration: The administration of IV normal saline

Study summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age \>18 years 2. Diagnosis of HAE Types I or II 3. Ability to provide evidence of HAE attacks to meet the screening requirement 4. Subjects must have access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks. 5. Adequate chemistry and hematology measures at screening 6. Subjects must agree not to participate in another interventional study for the duration of this trial. 7. Subjects must be capable of providing signed informed consent Exclusion Criteria: 1. Concurrent diagnosis of any other type of recurrent angioedema 2. Subjects who have known negative reaction or hypersensitivity to any lipid nanoparticles (LNP) component. 3. Any condition that, in the Investigator's opinion, could adversely affect the safety of the subject. 4. Unwilling to comply with study procedures.

Primary outcome measure(s)

  • Safety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs) — From NTLA-2002 infusion up to week 104 post-infusion
    (Phase 1 only)
  • Number of HAE attacks per month (Weeks 1-16) — From study drug infusion up to week 16 post-infusion
    (Phase 2 only)

Trial sites (9)

FacilityCityRegionStatus
Clinical Trial Site Campbelltown Australia
Clinical Trial Site Grenoble France
Clinical Trial Site Lille France
Clinical Trial Site Paris France
Clinical Trial Site Berlin Germany
Clinical Trial Site Frankfurt Germany
Clinical Trial Site Amsterdam Netherlands
Clinical Trial Site Auckland New Zealand
Clinical Trial Site Cambridge United Kingdom

More Intellia Therapeutics trials in the Netherlands

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Active, not recruiting
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 Enrolling by invitation
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Recruiting

Other trials for the same condition

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Active, not recruiting
Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 Enrolling by invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Enrolling by invitation
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05120830 on ClinicalTrials.gov ↗ ← All trials in the Netherlands